Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-614 · 1 trial · 1 indication
Blood and urine tests
Blood and urine tests
| Arm | Type | Description |
|---|---|---|
| ABT-614 | EXPERIMENTAL | - |
| Placebo Comparator | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-614 | DRUG | Active |
| Placebo Comparator | DRUG | Placebo |
Inclusion Criteria 1. Male or female aged between 19 and 70 years, inclusive, at time of consent. 2. Type 2 diabetes receiving at least one anti-diabetic medication for at least one year at the time of Screening. 3. Hemoglobin A1c \< 12% at the time of Screening. 4. Estimated glomerular filtration ...
ABT-614 is an investigational small molecule developed by Abbott Laboratories. It was studied in a Phase 1 clinical trial in adults with type 2 diabetes, chronic kidney disease, and protein in their urine. The trial evaluated its safety and tolerability and its effect on kidney function. It is not an approved medicine.
ABT-614 was studied in a Phase 1 trial in adults with type 2 diabetes and chronic kidney disease who had protein in their urine. The trial assessed the drug's safety and tolerability and its effect on kidney function. It is investigational and has no approved use.
ABT-614 is developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker ABT. Abbott sponsored the Phase 1 study of the drug in patients with type 2 diabetes and chronic kidney disease with protein in their urine.
ABT-614 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The study enrolled 16 participants. ABT-614 is investigational and has not been approved by the FDA for any indication.
ABT-614 has been studied in one completed Phase 1 trial, NCT01464320, titled a study to evaluate the safety and tolerability of ABT-614 and its effect on kidney function in subjects with type 2 diabetes and chronic kidney disease with protein in their urine. It was randomized, double-blind, placebo-controlled, and enrolled 16 participants in the United States.